These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 8544958)
1. In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment. Möller HE; Vermathen P; Ullrich K; Weglage J; Koch HG; Peters PE Neuropediatrics; 1995 Aug; 26(4):199-202. PubMed ID: 8544958 [TBL] [Abstract][Full Text] [Related]
2. Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria. Rupp A; Kreis R; Zschocke J; Slotboom J; Boesch C; Rating D; Pietz J J Cereb Blood Flow Metab; 2001 Mar; 21(3):276-84. PubMed ID: 11295882 [TBL] [Abstract][Full Text] [Related]
3. Brain imaging and proton magnetic resonance spectroscopy in patients with phenylketonuria. Möller HE; Weglage J; Bick U; Wiedermann D; Feldmann R; Ullrich K Pediatrics; 2003 Dec; 112(6 Pt 2):1580-3. PubMed ID: 14654669 [TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. Möller HE; Weglage J; Wiedermann D; Ullrich K J Cereb Blood Flow Metab; 1998 Nov; 18(11):1184-91. PubMed ID: 9809507 [TBL] [Abstract][Full Text] [Related]
5. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Schindeler S; Ghosh-Jerath S; Thompson S; Rocca A; Joy P; Kemp A; Rae C; Green K; Wilcken B; Christodoulou J Mol Genet Metab; 2007 May; 91(1):48-54. PubMed ID: 17368065 [TBL] [Abstract][Full Text] [Related]
6. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Weglage J; Pietsch M; Feldmann R; Koch HG; Zschocke J; Hoffmann G; Muntau-Heger A; Denecke J; Guldberg P; Güttler F; Möller H; Wendel U; Ullrich K; Harms E Pediatr Res; 2001 Apr; 49(4):532-6. PubMed ID: 11264437 [TBL] [Abstract][Full Text] [Related]
7. Future role of large neutral amino acids in transport of phenylalanine into the brain. Matalon R; Surendran S; Matalon KM; Tyring S; Quast M; Jinga W; Ezell E; Szucs S Pediatrics; 2003 Dec; 112(6 Pt 2):1570-4. PubMed ID: 14654667 [TBL] [Abstract][Full Text] [Related]
8. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pietz J; Kreis R; Boesch C; Penzien J; Rating D; Herschkowitz N Pediatr Res; 1995 Nov; 38(5):657-63. PubMed ID: 8552430 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo. Möller HE; Weglage J; Wiedermann D; Vermathen P; Bick U; Ullrich K Brain Res; 1997 Dec; 778(2):329-37. PubMed ID: 9459550 [TBL] [Abstract][Full Text] [Related]
10. Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Moats RA; Moseley KD; Koch R; Nelson M Pediatrics; 2003 Dec; 112(6 Pt 2):1575-9. PubMed ID: 14654668 [TBL] [Abstract][Full Text] [Related]
11. [Use of computerized neuropsychological tests and of nuclear magnetic resonance spectroscopy in clinical assessment of adult patients with phenylketonuria]. Bik-Multanowski M; Pietrzyk JJ Przegl Lek; 2011; 68(3):127-31. PubMed ID: 21812225 [TBL] [Abstract][Full Text] [Related]
12. [Differential diagnosis and therapy of various forms of hyperphenylalaninemia: facts and fiction]. Endres W Wien Klin Wochenschr; 1992; 104(16):503-9. PubMed ID: 1413808 [TBL] [Abstract][Full Text] [Related]
13. Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels. Martynyuk AE; Ucar DA; Yang DD; Norman WM; Carney PR; Dennis DM; Laipis PJ Epilepsia; 2007 Jun; 48(6):1143-50. PubMed ID: 17484755 [TBL] [Abstract][Full Text] [Related]
14. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients. Sitta A; Manfredini V; Biasi L; Treméa R; Schwartz IV; Wajner M; Vargas CR Mutat Res; 2009; 679(1-2):13-6. PubMed ID: 19665577 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. Leuzzi V; Bianchi MC; Tosetti M; Carducci CL; Carducci CA; Antonozzi I J Inherit Metab Dis; 2000 Sep; 23(6):563-70. PubMed ID: 11032331 [TBL] [Abstract][Full Text] [Related]
16. In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. Novotny EJ; Avison MJ; Herschkowitz N; Petroff OA; Prichard JW; Seashore MR; Rothman DL Pediatr Res; 1995 Feb; 37(2):244-9. PubMed ID: 7731764 [TBL] [Abstract][Full Text] [Related]
17. Proton NMR observation of phenylalanine and an aromatic metabolite in the rabbit brain in vivo. Avison MJ; Herschkowitz N; Novotny EJ; Petroff OA; Rothman DL; Colombo JP; Bachmann C; Shulman RG; Prichard JW Pediatr Res; 1990 Jun; 27(6):566-70. PubMed ID: 2162514 [TBL] [Abstract][Full Text] [Related]
18. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Møller LB; Paulsen M; Koch R; Moats R; Guldberg P; Güttler F Mol Genet Metab; 2005 Dec; 86 Suppl 1():S119-23. PubMed ID: 16176881 [TBL] [Abstract][Full Text] [Related]
19. [Differential diagnosis of increased phenylalanine blood level in infancy. Results of the German collaborative study on phenylketonuria (PKU)/hyperphenylalaninemia (HPA)]. Schmidt H; Lutz P; Batzler U Monatsschr Kinderheilkd; 1989 Feb; 137(2):86-92. PubMed ID: 2654616 [TBL] [Abstract][Full Text] [Related]
20. In vivo proton magnetic resonance spectroscopy in phenylketonuria. Möller HE; Ullrich K; Weglage J Eur J Pediatr; 2000 Oct; 159 Suppl 2():S121-5. PubMed ID: 11043158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]